NCT07141511View on ClinicalTrials.gov

A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

January 3, 2026

Study Completion Date

January 3, 2026

Conditions
Healthy Volunteers
Interventions
DRUG

BG-71332

Administered orally

DRUG

Zanubrutinib

Administered orally

DRUG

Sonrotoclax

Administered orally

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY